Can RepliCel Life Sciences Inc’s Tomorrow be Different? The Stock Declines Again

 Can RepliCel Life Sciences Inc's Tomorrow be Different? The Stock Declines Again

The stock of RepliCel Life Sciences Inc (CVE:RP) is a huge mover today! About 22,000 shares traded hands or 84.98% up from the average. RepliCel Life Sciences Inc (CVE:RP) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.
The move comes after 9 months negative chart setup for the $10.98M company. It was reported on Nov, 28 by Barchart.com. We have $0.79 PT which if reached, will make CVE:RP worth $329,400 less.

More important recent RepliCel Life Sciences Inc (CVE:RP) news were published by: Marketwired.com which released: “RepliCel Life Sciences Announces Closing of Private Placement” on October 31, 2016, also Midasletter.com published article titled: “RepliCel Life Sciences Inc. CEO David Hall Interview and Podcast”, Prnewswire.com published: “RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype” on July 29, 2015. More interesting news about RepliCel Life Sciences Inc (CVE:RP) was released by: Marketwired.com and their article: “RepliCel Announces CEO Update” with publication date: February 16, 2016.

RepliCel Life Sciences Inc. is a regenerative medicine firm focused on developing autologous cell therapies that treat functional cellular deficits. The company has a market cap of $10.98 million. The Company’s product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. It currently has negative earnings. RCT-01 is an autologous cell treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment